Last reviewed · How we verify
NCT07005050
Renal Pelvic Denervation Pilot Trial
NA trial testing RPD in Uncontrolled Hypertension in 60 participants. Currently enrolling.
30 October 2026
Quick facts
| Lead sponsor | Verve Medical, Inc |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 30 December 2025 |
| Primary completion | 30 October 2026 |
| Estimated completion | 2 March 2029 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- RPD
- Active hypertension medical therapy — full drug profile →
Conditions studied
- Uncontrolled Hypertension — all drugs for Uncontrolled Hypertension →
Sponsor
Verve Medical, Inc — full company profile →
Who can join
Adults 21 to 80, any sex, with Uncontrolled Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose. The novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07005050
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uncontrolled Hypertension
Currently open trials in the same condition.
- NCT06610448 — Wearable Evaluation of Ambulatory Readings for Blood Pressure · NA · recruiting
- NCT06926855 — Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes · NA · active not recruiting
- NCT06344104 — A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or Mo · Phase 3 · active not recruiting
- NCT06938633 — Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry · NA · recruiting
- NCT07049289 — Telemonitoring in Arterial Hypertension · NA · active not recruiting
Other Verve Medical, Inc trials
Trials by the same sponsor.
- NCT05440513 — A Study of Non-Vascular Renal Denervation Using the Verve Medical Phoenix ™ System · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07005050 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Verve Medical, Inc
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07005050.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing